Figure 2.
Figure 2. VP16-Meis is independently oncogenic. (A) Schematic representation of Meis1 mutants. (B) Western blot analysis of MEIS1 levels in the transduced GP + E cells. MEIS1 antibody recognizes N-terminal 30 amino acids of MEIS1 (left). VP16 fusion proteins were detected using anti-VP16 antibody (right panel). Nonspecific bands at approximately 70 kDa and approximately 75 kDa on the left and the right panel, respectively, serve as loading controls. (C) Survival curves of mice that received a transplant of HOXA9, HOXA9 plus Meis1, HOXA9 plus Meis1Δ334, HOXA9 plus VP16-Meis1, or HOXA9 plus VP16-Meis1Δ334 cells. (D) Survival curves of mice that received a transplant of HOXA9, VP16-Meis1, or VP16-Meis1Δ334 cells. Note that control HOXA9 mice are the same as in Figure 1C.

VP16-Meis is independently oncogenic. (A) Schematic representation of Meis1 mutants. (B) Western blot analysis of MEIS1 levels in the transduced GP + E cells. MEIS1 antibody recognizes N-terminal 30 amino acids of MEIS1 (left). VP16 fusion proteins were detected using anti-VP16 antibody (right panel). Nonspecific bands at approximately 70 kDa and approximately 75 kDa on the left and the right panel, respectively, serve as loading controls. (C) Survival curves of mice that received a transplant of HOXA9, HOXA9 plus Meis1, HOXA9 plus Meis1Δ334, HOXA9 plus VP16-Meis1, or HOXA9 plus VP16-Meis1Δ334 cells. (D) Survival curves of mice that received a transplant of HOXA9, VP16-Meis1, or VP16-Meis1Δ334 cells. Note that control HOXA9 mice are the same as in Figure 1C.

Close Modal

or Create an Account

Close Modal
Close Modal